Skip to main content

Table 2 Description of wait times to definitive surgery, radiotherapy and chemotherapy overall, and among women diagnosed with screened, interval and symptomatic breast cancers

From: Factors associated with wait times across the breast cancer treatment pathway in Ontario

 

Overall

Screen-detected

Interval

Symptomatic

 

N = 1760

N = 1096

N = 309

N = 355

 

N (%)

N (%)

N (%)

N (%)

Treatments Received a

    

Surgery + Chemotherapy

110 (6.3)

60 (5.5)

20 (6.5)

30 (8.5)

Surgery + Radiotherapy

838 (47.6)

570 (52.0)

139 (45.0)

129 (36.2)

Surgery + Chemotherapy + Radiotherapy

552 (31.4)

308 (29.0)

112 (36.2)

132 (37.2)

Surgery Only

260 (14.8)

158 (14.4)

38 (12.3)

64 (18.0)

Diagnosis to Definitive Surgery b

    

Number In analysis

N = 1675

N = 1056

N = 293

N = 326

Median Wait Time to Definitive Surgery

17 days

18 days

20 days

15 days

IQR

0-31 days

0-31 days

0-33 days

0-30 days

90th Percentile >

49 days

49 days

51 days

49 days

Final Surgery to Chemotherapy c

    

Number in analysis

N = 498

N = 290

N = 98

N = 110

Median Wait Time to Chemotherapy

44 days

43 days

43 days

46 days

IQR

34-56 days

33-56 days

35-58 days

34-54 days

90th Percentile >

70 days

71 days

71 days

66 days

Final Surgery to Radiotherapy d

    

Number In analysis

N = 812

N = 556

n = 132

N = 124

Median Wait Time to Radiotherapy

75 days

75 days

73.5 days

78 days

IQR

57-97 days

57-96 days

59-97 days

59-100 days

90th Percentile >

118 days

118 days

112 days

138 days

  1. aPearson chi-squared test; difference in treatments received for interval (p = 0.031) and symptomatic (p < 0.001) compared to screen-detected.
  2. bWilcoxon rank sum test; difference in wait times for interval (p = 0.137) and symptomatic (p = 0.191) compared to screen-detected.
  3. cWilcoxon rank sum test; difference in wait times for interval (p = 0.504) and symptomatic (p = 0.573) compared to screen-detected.
  4. dWilcoxon rank sum test; difference in wait times for interval (p = 911) and symptomatic (p = 0.170) compared to screen-detected.